文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗特应性皮炎的皮肤神经解剖与细胞反应

Cutaneous Neuroanatomical and Cellular Response to Dupilumab Treatment in Atopic Dermatitis.
PubMed 文献 · J Invest Dermatol · 2025-08-22

该研究对49例重度特应性皮炎成人患者在接受度普利尤单抗300 mg每2周皮下注射16周前后的皮肤活检和血液进行分析,发现治疗可改善表皮内神经纤维密度和异常性瘙痒,并与紧密连接形成、IL受体及神经支配相关介质表达下降以及血液免疫细胞亚群变化相关。

要点

  • 度普利尤单抗治疗16周可改善表皮内神经纤维密度和异常性瘙痒。
  • 紧密连接形成与表皮内神经纤维生长水平相关。
  • 治疗伴随IL4R、IL13RA1、IL13RA2及NGF、SEMA3A表达下降和血液免疫细胞变化。

核心结论

  • IL4Rα抗体治疗与皮肤神经解剖改善和神经元敏化减少相平行,并伴有相关生物标志物改善。

研究设计与样本

  • 对49例接受度普利尤单抗300 mg每2周皮下注射共16周的重度特应性皮炎成人患者,在初始评估和随访时分析皮肤活检和血液。

主要发现

  • 初始评估时瘙痒性皮损和非瘙痒性非皮损皮肤的表皮内神经纤维密度降低、异常性瘙痒增加,度普利尤单抗治疗后改善。
  • 紧密连接形成(claudin-1染色)与表皮内神经纤维生长水平相关。
  • 初始评估时瘙痒性皮损中靶向IL受体(IL4R、IL13RA1、IL13RA2)和神经支配密度相关介质(NGF、SEMA3A)表达较非瘙痒性非皮损皮肤和随访时愈合的原瘙痒性皮损增加。
  • 随访时血液CD8+中央记忆T细胞和CD4+CD25+CD127-细胞(包括调节性T细胞)增加,CD8效应T细胞和CLA+活化CD4+细胞减少。

临床怎么用

  • 度普利尤单抗治疗可改善特应性皮炎患者的皮肤神经解剖异常和神经元敏化,支持其缓解瘙痒的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Itch is the dominant symptom in atopic dermatitis. Cutaneous neuronal alterations underlying this symptom are still poorly understood. Therefore, we aimed at deciphering cutaneous neuronal alterations during atopic dermatitis treatment with dupilumab. Skin biopsies and blood from 49 adult patients with severe atopic dermatitis receiving 300 mg dupilumab subcutaneously every 2 weeks over a period of 16 weeks were analyzed at initial assessment and at follow-up for intraepidermal nerve fiber density, alloknesis, and biomarkers. Decreased intraepidermal nerve fiber density and increased alloknesis in pruritic lesional and nonpruritic nonlesional skin at initial assessment improved after dupilumab treatment. Formation of tight junctions (claudin-1 staining) was correlated with the epidermal level of intraepidermal nerve fiber growth. Expressions of targeted IL receptors (IL4R, IL13RA1, IL13RA2) and mediators related to innervation density (NGF, SEMA3A) were increased in pruritic lesion skin at initial assessment compared with those in nonpruritic nonlesional skin at initial assessment and former pruritic lesional skin/healed at follow-up. Blood CD8+ central memory T cells and CD4+ CD25+ CD127- cells, including regulatory T cells, increased at follow-up; CD8 T-effector cells and CLA+ activated CD4+ cells decreased. In conclusion, treatment with an IL4Rα antibody is paralleled by an improvement of neuroanatomy and a reduction of neuronal sensitization, paralleled by relevant biomarker improvement.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Wiegmann H, Witte F, Renkhold L, et al. Cutaneous Neuroanatomical and Cellular Response to Dupilumab Treatment in Atopic Dermatitis. J Invest Dermatol. 2025. PMID: 40850651. doi:10.1016/j.jid.2025.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。